FOLICTA
Folicta contains L-Methylfolate (5-MTHF), which is the primary, biologically active form of folate circulating in human plasma
Active Clinical Composition: L-Methylfolate
₨ 380
Folicta contains L-Methylfolate (5-MTHF), which is the primary, biologically active form of folate circulating in human plasma
₨ 380
Mechanism of Action: Folicta contains L-Methylfolate (5-MTHF), which is the primary, biologically active form of folate circulating in human plasma:
Bypassing Enzymatic Bottlenecks (MTHFR Polymorphisms): Standard synthetic folic acid requires a complex, multi-step enzymatic conversion—primarily driven by the enzyme methylenetetrahydrofolate reductase (MTHFR)—to become biologically active. Genetic variations in the MTHFR gene (common in 40-50% of the population) impair this conversion, leading to metabolic stalls and elevated embryotoxic homocysteine. L-Methylfolate completely bypasses these enzymatic bottlenecks, entering the cellular folate pool directly.
Homocysteine Remethylation: Acts as a vital methyl donor in the conversion of homocysteine back into methionine, protecting microvascular beds and reducing cardiovascular and placental toxicity.
DNA Synthesis & Neurodevelopment: Facilitates purine and pyrimidine synthesis, ensuring proper cell division, rapid tissue growth during gestation, and the synthesis of key monoamine neurotransmitters (serotonin, dopamine, and norepinephrine).
Folicta is clinically indicated for:
Neural Tube Defect (NTD) Prophylaxis: Essential pre-conception and first-trimester prophylaxis to prevent neural tube defects (such as spina bifida and anencephaly).
MTHFR Gene Polymorphism Management: The preferred folate therapy for patients with known MTHFR C677T or A1298C mutations who cannot efficiently process standard synthetic folic acid.
Recurrent Pregnancy Loss (RPL) & Placental Vascular Defense: Lowers elevated homocysteine levels that threaten microvascular blood flow to the developing placenta.
Megaloblastic Anemia & Fatigue: Corrects folate-deficiency-induced macrocytic anemia and restores cellular energy production.
| Active Substance | Strength per Unit |
|---|---|
| L-Methylfolate | 400mcg |
* Excipients and coating agents not listed. Refer to full SMPC for complete profile.
Standard Dose: One (1) tablet daily, or as directed by a registered medical practitioner.
Preconception & Pregnancy Regimen: Recommended to initiate prior to conception and continue throughout pregnancy and lactation to support maternal-fetal health.
Administration: Oral administration, can be taken with or without food.
Absolute Contraindications: Hypersensitivity to L-methylfolate or any excipients in the formulation.
Safety Advantage over Synthetic Folic Acid: Unlike high-dose synthetic folic acid, L-methylfolate does not result in the accumulation of Unmetabolized Folic Acid (UMFA) in the systemic circulation, providing a superior and safer physiological profile.
Precautions: Folate therapy alone should not be used to treat Addison’s pernicious anemia or other vitamin B12 deficiency states, as it may mask neurological progression unless co-administered with adequate B12.
Aleena Abid –
Folicta has been a crucial part of my pregnancy journey. It’s comforting to know that I’m supporting my baby’s health right from the start. The added energy and peace of mind are invaluable benefits that I’ve experienced while taking this supplement.